Oxford Nanopore Technologies Revenue and Competitors

Oxford, UK

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Oxford Nanopore Technologies's estimated annual revenue is currently $334.6M per year.(i)
  • Oxford Nanopore Technologies's estimated revenue per employee is $248,000
  • Oxford Nanopore Technologies's current valuation is $1.6B.

Employee Data

  • Oxford Nanopore Technologies has 1349 Employees.(i)
  • Oxford Nanopore Technologies grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4280M9130-4%$28M$63.3B
#2
$49.1M2693%N/AN/A
Add Company

Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be introduced and workflows will be further simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in >50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field. Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The the high-throughput/sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.

keywords:Agriculture,Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

N/A

Total Funding

1349

Number of Employees

$334.6M

Revenue (est)

11%

Employee Growth %

$1.6B

Valuation

N/A

Accelerator

Oxford Nanopore Technologies's People

NameTitleEmail/Phone
1
Director Distribution & LATAMReveal Email/Phone
2
Director, Sales Training, AmericasReveal Email/Phone
3
Director, Technical Services (Production Scale Sequencing)Reveal Email/Phone
4
Director Inside Sales - AmericasReveal Email/Phone
5
Senior Technical Applications SpecialistReveal Email/Phone
6
Clinical Bioinformatics Lead, Associate DirectorReveal Email/Phone
7
Director Clinical Segment MarketingReveal Email/Phone
8
Nanopore Account ExecutiveReveal Email/Phone
9
Account ExecutiveReveal Email/Phone
10
Commercial Marketing ManagerReveal Email/Phone

Oxford Nanopore Technologies News

2022-04-13 - Oxford Nanopore Technologies Limited (LON:ONT) Insider ...

Oxford Nanopore Technologies Limited develops and commercializes a technology platform using nanopore-based sensing for the analysis of various...

2022-03-30 - IP : Oxford Nanopore Technologies plc - Shows new high-accuracy, high-output chemistry

Oxford Nanopore's technology sequences DNA or RNA molecules of any length, from short to ultra-long. It is the only technology on the market...

2022-03-30 - Oxford Nanopore Technologies Settles Contract Dispute With ...

NEW YORK - Oxford Nanopore Technologies (ONT) announced on Friday that it has reached "an amicable resolution" with the UK Department of...

2021-09-16 - Oxford Nanopore to Raise GBP300 Million in London IPO -- Update

By Jaime Llinares Taboada Oxford Nanopore Technologies Ltd. said Thursday that it intends to raise around 300 million pounds ($415.3 million) at its initial public offering in London, half of which will be provided by Texas-based software provider Oracle Corp. The DNA-sequencing specialist, wh ...

2021-09-16 - Oxford Nanopore to Raise GBP300 Million in London IPO

By Jaime Llinares Taboada Oxford Nanopore Technologies Ltd. said Thursday that it intends to raise around 300 million pounds ($415.3 million) at its initial public offering in London, half of which will be provided by Texas-based software provider Oracle Corp. The DNA-sequencing specialist, wh ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1430M1495-1%$80M
#2
$500.1M20814%N/A
#3
$531.7M2110N/AN/A
#4
$1083M25026%N/A
#5
$300M35134%N/A

Oxford Nanopore Technologies Executives


NameTitle
Gordon SangheraChief Executive Officer
Spike WillcocksCHIEF BD OFFICER
Clive BrownChief Technology Officer
Tim CowperCFO
John M.Chief Scientific Officer
John MiltonChief Scientific Officer
Zoe McDougallVP, CORPORATE AND COMMUNICATIONS
Kristy Loomis - SPHRSenior Vice President Product Management
Bob ArsenaultVP and General Counsel
Andy DaviesVP Global IT & Digital
James ClarkeVice President of Platform Technology
Lakmal JayasingheVP, R&D - Biologics
Rhodri DaviesVP Operations
Martyn AndrewsVP Intellectual Property
Dan TurnerVP, Applications
Sarah Lapworth MCIPDVP, Global HR
Richard ComptonSenior Vice President of Commercial Operations
Anthony JonesVP, Engineering at Oxford Nanopore Technologies Ltd
Stuart ReidVP Development
Zoe McDougallVP Marketing and Corporate Affairs
Louisa LudbrookVP, Global Sales
Nirmala SantiapillaiVice President, Global Service
Christopher BrownVice President, Strategic Programmes
Rosemary DokosVP, Product & Programme Management
Roger PettettVP, Informatics
Emma StantonVP, Clinical
Rhodri DaviesVP, Operations
Chris BrownVP, Strategic Programmes
Kristen StoopsVP, Business Development
Howard OrmanVP, Tech Transfer, Quality & Regulatory
John SchoellermanSVP, Corporate Development and Investment
Jordan HermanVP, GENERAL COUNSEL